Eli Lilly and the state of the insulin battle (SeekingAlpha) - Oct 8, 2012 - FDA delayed the decision on Tresiba until 2013; P3 clinical data for the Lilly drug LY2605541 is expected in 2013
Anticipated P3 data: top line • Regulatory • Diabetes
|
|
..Besides Lilly, Novo is planning to challenge Lantus with their candidate Tresiba or degludec. This summer the FDA delayed the decision on Tresiba until 2013.
Phase 3 clinical data for the Lilly drug LY2605541 is expected in 2013, suggesting it will be snapping at Tresiba's heels.
|